The phase 2 trial showed a 42% response rate with lete-cel in synovial sarcoma and MRCLS, with manageable adverse events.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Well Differentiated Liposarcoma.

Because liposarcoma is rare, commonly recurs, and has evolving treatments, it cannot be overemphasized that patients should be referred to specialized cancer treatment centers where a larger ...

Earlier this week, the American Cancer Society released the full list of 245 new and renewed research grants that were ...

The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study (INVINCIBLE-3) in Metastatic Soft ...

Years ago, a family member was diagnosed with an extremely rare cancer: Liposarcoma of the Spermatic Cord. Fewer than... The ...

In a recent transaction, William C. Bertrand Jr., the Chief Operating Officer of Adaptimmune Therapeutics PLC (NASDAQ:ADAP), ...

The Cork native has lost three members of her family from cancer. The Irish TV star lost her dad Sean to liposarcoma, a rare and incurable cancer when she was just 23. This Christmas ...

In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...